The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.
 
Stephen J. Freedland
Employment - Genomic Health (I)
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Ferring; Janssen Biotech; Myovant Sciences; Pfizer; Sanofi
Research Funding - Bayer (Inst); Diasorin; GenomeDx (Inst); Janssen Biotech (Inst); MDxHealth (Inst); Merck; Myriad Genetics (Inst); OPKO Diagnostics (Inst); Progenika (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Rickard Sandin
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Janvi Sah
Employment - STATinMED Research
 
Birol Emir
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Qiao Mu
Employment - STATinMED Research
 
Anna Ratiu
Employment - STATinMED Research
 
Agnes Hong
Employment - Astellas Pharma
Stock and Other Ownership Interests - Roche
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma
 
Lucile Serfass
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Dendreon; Endocyte; Genentech; Genomic Health; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics; Telix Pharmaceuticals